Brief: HBM Holdings Decided To Close Study Without Enrolling New Patients Of Its China Tanfanercept Phase III Clinical Trial
10/10/2022 11:59
Oct 10 (Reuters) - Hbm Holdings Ltd 2142.HK :
* DECIDED TO CLOSE STUDY WITHOUT ENROLLING NEW PATIENTS OF
ITS
CHINA TANFANERCEPT PHASE III CLINICAL TRIAL
Further company coverage: 2142.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HBM Holdings
See all newsBrief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study